Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included 154 patients with IBD: 78 UC patients (50.6%)...

Celý popis

Podrobná bibliografie

Hlavní autoři:	O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov
Médium:	Artigo
Jazyk:	Russo
Vydáno:	"Consilium Medicum" Publishing house 2021-02-01
Edice:	Терапевтический архив
Témata:	biosimilar crohn’s disease inflammatory bowel disease infliximab ulcerative colitis
On-line přístup:	https://ter-arkhiv.ru/0040-3660/article/viewFile/64705/47582
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!